FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226103678> ?p ?o ?g. }

• W4226103678 endingPage "836" @default.
• W4226103678 startingPage "826" @default.
• W4226103678 abstract "Objective The aim of this study was to investigate the toxicological profile of gadopiclenol, a new high-relaxivity macrocyclic gadolinium-based contrast agent (GBCA), in renally impaired rats, in comparison with 2 other macrocyclic GBCAs, gadoterate meglumine and gadobutrol, and 1 linear and nonionic GBCA, gadodiamide. Methods Renal failure was induced by adding 0.75% wt/wt adenine to the diet for 3 weeks. During the second week of adenine-enriched diet, the animals (n = 8/group × 5 groups) received 5 consecutive intravenous injections of GBCA at 2.5 mmol/kg per injection, resulting in a cumulative dose of 12.5 mmol/kg or saline followed by a 3-week treatment-free period after the last injection. The total (elemental) gadolinium (Gd) concentration in different tissues (brain, cerebellum, femoral epiphysis, liver, skin, heart, kidney, spleen, plasma, urine, and feces) was measured by inductively coupled plasma mass spectrometry. Transmission electron microscopy (and electron energy loss spectroscopy analysis of metallic deposits) was used to investigate the presence and localization of Gd deposits in the skin. Relaxometry was used to evaluate the presence of dissociated Gd in the skin, liver, and bone. Skin histopathology was performed to investigate the presence of nephrogenic systemic fibrosis–like lesions. Results Gadodiamide administrations were associated with high morbidity-mortality but also with macroscopic and microscopic skin lesions in renally impaired rats. No such effects were observed with gadopiclenol, gadoterate, or gadobutrol. Overall, elemental Gd concentrations were significantly higher in gadodiamide-treated rats than in rats treated with the other GBCAs for all tissues except the liver (where no significant difference was found with gadopiclenol) and the kidney and the heart (where statistically similar Gd concentrations were observed for all GBCAs). No plasma biochemical abnormalities were observed with gadopiclenol or the control GBCAs. Histopathology revealed a normal skin structure in the rats treated with gadopiclenol, gadoterate, and gadobutrol, contrary to those treated with gadodiamide. No evidence of Gd deposits on collagen fibers and inclusions in fibroblasts was found with gadopiclenol and its macrocyclic controls, unlike with gadodiamide. Animals of all test groups had Gd-positive lysosomal inclusions in the dermal macrophages. However, the textures differed for the different products (speckled texture for gadodiamide and rough-textured appearance for the 2 tested macrocyclic GBCAs). Conclusions No evidence of biochemical toxicity or pathological abnormalities of the skin was observed, and similar to other macrocyclic GBCAs, gadoterate and gadobutrol, tissue retention of Gd was found to be low (except in the liver) in renally impaired rats treated with the new high-relaxivity GBCA gadopiclenol." @default.
• W4226103678 created "2022-05-05" @default.
• W4226103678 creator A5016040044 @default.
• W4226103678 creator A5026920309 @default.
• W4226103678 creator A5034484376 @default.
• W4226103678 creator A5042622456 @default.
• W4226103678 creator A5048991357 @default.
• W4226103678 creator A5055781740 @default.
• W4226103678 creator A5065874712 @default.
• W4226103678 creator A5085134628 @default.
• W4226103678 date "2021-06-07" @default.
• W4226103678 modified "2023-10-14" @default.
• W4226103678 title "Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure" @default.
• W4226103678 cites W1588625263 @default.
• W4226103678 cites W1833314573 @default.
• W4226103678 cites W1976690287 @default.
• W4226103678 cites W1978587722 @default.
• W4226103678 cites W2015842349 @default.
• W4226103678 cites W2019842087 @default.
• W4226103678 cites W2031557262 @default.
• W4226103678 cites W2031948766 @default.
• W4226103678 cites W2033503179 @default.
• W4226103678 cites W2039503809 @default.
• W4226103678 cites W2053564324 @default.
• W4226103678 cites W2061948232 @default.
• W4226103678 cites W2062381788 @default.
• W4226103678 cites W2077853709 @default.
• W4226103678 cites W2091470298 @default.
• W4226103678 cites W2104738562 @default.
• W4226103678 cites W2106396508 @default.
• W4226103678 cites W2109768646 @default.
• W4226103678 cites W2110641747 @default.
• W4226103678 cites W2140036864 @default.
• W4226103678 cites W2142716296 @default.
• W4226103678 cites W2159120715 @default.
• W4226103678 cites W2310739815 @default.
• W4226103678 cites W2328699588 @default.
• W4226103678 cites W2333106507 @default.
• W4226103678 cites W2485693178 @default.
• W4226103678 cites W2505724533 @default.
• W4226103678 cites W2519041107 @default.
• W4226103678 cites W2558476943 @default.
• W4226103678 cites W2582537586 @default.
• W4226103678 cites W2751885695 @default.
• W4226103678 cites W2783216098 @default.
• W4226103678 cites W2792058008 @default.
• W4226103678 cites W2797339581 @default.
• W4226103678 cites W2801750152 @default.
• W4226103678 cites W2804213255 @default.
• W4226103678 cites W2832750138 @default.
• W4226103678 cites W2899323505 @default.
• W4226103678 cites W2899663376 @default.
• W4226103678 cites W2921998404 @default.
• W4226103678 cites W2922006240 @default.
• W4226103678 cites W2931677153 @default.
• W4226103678 cites W2982371538 @default.
• W4226103678 cites W2982408692 @default.
• W4226103678 cites W2983525439 @default.
• W4226103678 cites W2999830370 @default.
• W4226103678 cites W3016386976 @default.
• W4226103678 cites W3046014930 @default.
• W4226103678 doi "https://doi.org/10.1097/rli.0000000000000793" @default.
• W4226103678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34091462" @default.
• W4226103678 hasPublicationYear "2021" @default.
• W4226103678 type Work @default.
• W4226103678 citedByCount "5" @default.
• W4226103678 countsByYear W42261036782021 @default.
• W4226103678 countsByYear W42261036782022 @default.
• W4226103678 countsByYear W42261036782023 @default.
• W4226103678 crossrefType "journal-article" @default.
• W4226103678 hasAuthorship W4226103678A5016040044 @default.
• W4226103678 hasAuthorship W4226103678A5026920309 @default.
• W4226103678 hasAuthorship W4226103678A5034484376 @default.
• W4226103678 hasAuthorship W4226103678A5042622456 @default.
• W4226103678 hasAuthorship W4226103678A5048991357 @default.
• W4226103678 hasAuthorship W4226103678A5055781740 @default.
• W4226103678 hasAuthorship W4226103678A5065874712 @default.
• W4226103678 hasAuthorship W4226103678A5085134628 @default.
• W4226103678 hasBestOaLocation W42261036781 @default.
• W4226103678 hasConcept C126322002 @default.
• W4226103678 hasConcept C126894567 @default.
• W4226103678 hasConcept C142724271 @default.
• W4226103678 hasConcept C178790620 @default.
• W4226103678 hasConcept C185592680 @default.
• W4226103678 hasConcept C2776875665 @default.
• W4226103678 hasConcept C2780026267 @default.
• W4226103678 hasConcept C2780091579 @default.
• W4226103678 hasConcept C2781027423 @default.
• W4226103678 hasConcept C2989005 @default.
• W4226103678 hasConcept C544855455 @default.
• W4226103678 hasConcept C557651011 @default.
• W4226103678 hasConcept C71924100 @default.
• W4226103678 hasConceptScore W4226103678C126322002 @default.
• W4226103678 hasConceptScore W4226103678C126894567 @default.
• W4226103678 hasConceptScore W4226103678C142724271 @default.
• W4226103678 hasConceptScore W4226103678C178790620 @default.
• W4226103678 hasConceptScore W4226103678C185592680 @default.
• W4226103678 hasConceptScore W4226103678C2776875665 @default.

• next